"The first clinical trial of a drug that targets one form of mutant KRAS for degradation has shown signs of success. Four large clinical trials are testing another drug that inhibits several different mutant forms of KRAS and related proteins."
"KRAS belongs to the RAS family of proteins, which have key roles in cell growth and proliferation. Some KRAS mutations lock the protein in an 'on' position, leading to the uncontrolled cellular growth that is a hallmark of cancer."
"When chemists finally found compounds that could bind to and disable mutant KRAS, the drugs turned out to be effective for only a short period of time. In every patient, we see resistance developing."
KRAS mutations drive some of the deadliest cancers, making it a critical target for drug development. Recent clinical trials have shown success in targeting mutant KRAS for degradation. Four additional trials are underway to inhibit various mutant forms of KRAS. Experts believe these approaches may not cure cancer alone but could be combined with other treatments for better outcomes. KRAS mutations keep the protein in an active state, leading to uncontrolled cell growth, complicating drug development due to the protein's smooth surface and resistance issues.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]